Efficacy and safety of Vibegron for the treatment of residual overactive bladder symptoms after laser vaporization of the prostate: A single‐center prospective randomized controlled trial (VAPOR TRIAL) | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Efficacy and Safety of Vibegron Add‐On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α <sub>1</sub> ‐Blocker Treatment: A Multi‐Center Prospective Randomized Controlled Study ( <scp>VATON</scp> Study)RCT · 2026 · 3 citations
2Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial2025 · 2 citations
3Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE TrialRCT · 2025 · 1 citations
4P2-12 EFFICACY AND SAFETY OF VIBEGRON IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND SYMPTOMS OF OVERACTIVE BLADDER: RESULTS FROM THE PHASE 3 RANDOMIZED CONTROLLED COURAGE TRIAL2024
5Safety and Efficacy of Vibegron in Men With Overactive Bladder Symptoms on Pharmacotherapy for Benign Prostatic Hyperplasia: Results From the 28-Week Open-Label COURAGE Extension Trial Completing the 52-Week Phase 3 EvaluationHuman Clinical Trial · 2026 · 3 citations
6Editorial Comment: Safety and Efficacy of Vibegron in Men With Overactive Bladder Symptoms on Pharmacotherapy for Benign Prostatic Hyperplasia: Results From the 28-Week Open-Label COURAGE Extension Trial Completing the 52-Week Phase 3 Evaluationeditorial · 2026 · 1 citations
7Efficacy of Vibegron in Overactive Bladder: A Bayesian Cross‐Trial Synthesis of Benefit Probabilities and Decision ThresholdsHuman Clinical Trial · 2026
8Impact of vibegron on quality of life in men with overactive bladder receiving treatment for benign prostatic hyperplasia: patient-reported outcomes from the randomized placebo-controlled COURAGE trialRCT · 2026
9Impact of Histopathology and Bladder Dysfunction on the Treatment Strategy Selection of Ketamine‐Associated CystitisLUTS Lower Urinary Tract Symptoms · 2026
10Phenotyping Interstitial Cystitis/Bladder Pain Syndrome: Clinical and Mechanistic Evidence, Candidate Biomarkers, and Implications for ManagementLUTS Lower Urinary Tract Symptoms · 2026

More from LUTS Lower Urinary Tract Symptoms

More from Kyorin University